Trial Profile
NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Samotolisib (Primary)
- Indications Bone metastases; CNS cancer; Neuroblastoma; Non-Hodgkin's lymphoma; Solid tumours
- Focus Therapeutic Use
- Acronyms Pediatric MATCH
- 03 Oct 2023 Planned End Date changed from 30 Sep 2024 to 1 Oct 2024.
- 30 May 2023 Status changed from recruiting to active, no longer recruiting.
- 10 May 2022 Status changed from suspended to recruiting.